{"filing":{"accession_number":"0001213900-26-064278","cik":"0001860657","ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"ea0293097-8k_allarity.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026064278/ea0293097-8k_allarity.htm"},"events":[{"id":2854,"run_id":2480,"accession_number":"0001213900-26-064278","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"Allarity Therapeutics amended and restated its Management Services Agreement with CEO Thomas H. Jensen, effective June 1, 2026, materially modifying his compensation structure and termination benefits. Changes include revised base salary components (SEK 6,000,000 and US$163,043), elimination of a $100,000 signing bonus, annual bonus cap at 60% of monthly fees, and enhanced severance provisions including increased notice period (15 to 30 days), new 12-month termination payment upon convenience termination, and modified Good Reason severance (9 months to 12 months of monthly fees).","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-06-02","items":[{"id":3653,"accession_number":"0001213900-26-064278","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.35,"reasoning":"The section header indicates Item 5.02 disclosure covering departures, elections, appointments, and/or compensatory arrangements, but the actual prose content was not provided. Without the specific details of what occurred (e.g., whether an executive departed, was appointed, received compensation, or some combination), I cannot reliably classify this into a more specific event type. I am marking it as material because Item 5.02 disclosures typically involve material executive changes, but the confidence is low due to missing content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:05.690972+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3653,"accession_number":"0001213900-26-064278","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.35,"reasoning":"The section header indicates Item 5.02 disclosure covering departures, elections, appointments, and/or compensatory arrangements, but the actual prose content was not provided. Without the specific details of what occurred (e.g., whether an executive departed, was appointed, received compensation, or some combination), I cannot reliably classify this into a more specific event type. I am marking it as material because Item 5.02 disclosures typically involve material executive changes, but the confidence is low due to missing content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:38:05.690972+00:00","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-06-02"}]}